Drug Profile
Research programme: salmonella vaccine - Syntiron
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Syntiron LLC
- Developer Epitopix
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Salmonella infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Salmonella-infections in USA
- 12 Nov 2010 Syntiron receives a Qualifying Therapeutic Discovery Project grant for its bacterial vaccine development programme
- 20 Oct 2006 Preclinical trials in Salmonella infections in USA (unspecified route)